When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
HOOK - Hookpia doses first patient in mid-stage HB-201 study
HOOKIPA Pharma Inc.
HOOKIPA Pharma (NASDAQ:HOOK) doses first patient in a Phase 1/2 clinical trial (NCT04180215) of HB-201, an immunotherapy for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers. This trial is HOOKIPA’s first clinical trial in immuno-oncology.
More news on: HOOKIPA Pharma Inc., Healthcare stocks news,